Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 22, 2003

View Archived Issues

New tricyclic macrolide antibiotics identified at Abbott

Merck describes new selective androgen receptor modulators for osteoporosis therapy

Another series of chemokine CCR2 modulators newly identified at Merck

Novel anti-herpes virus agents prepared and tested by GSK team

Genelabs patent covers new NS5B inhibitors for HCV infection

Pivotal stage of AI-700 phase III program commences

Kinexium to manage development of new departments at Generex

Phase I trial tests FG-3019 in IPF patients

Second approvable letter for Symlin

Naropin recommended for E.U. approval for new indication

Second phase II trial for Corus-1030

CTCE-9908 enters phase I testing

Enrollment goal reached for phase III Xibrom trial

Orphan drug designation for Photopoint MV-2101

BAMF Technology to be transitioned to Eclipse Diagnostics

Oxford BioMedica oncology pipeline update

deCODE achieves milestones in Roche DNA-based diagnostics alliance

MLN-2222 enters phase I

Clinical effects of PKC-412 in acute myeloid leukemia

Antitumor activity of thalidomide analogues in hematological malignancies

Cardioprotection against ischemia/reperfusion injury via PPARalpha activation shown in mice

Septic diaphragm dysfunction attenuated with geranylgernaylacetone induction of HSD70 in rats

NDA for lower dose Yasmin accepted for filing

XTL Biopharmaceuticals reviews recent developments

GW-4064, a FXR agonist, provides hepatoprotection in rat models of cholestasis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
HX-16108 holds promise for treating inflammatory skin diseases
BioWorld Science
Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has...